Biocon Biologics integrates Vitaris’ biosimilars business
NEW DELHI : Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, on Monday announced a complete integration of the acquired Vitaris’ biosimilars business in 120 countries, a year ahead of schedule. The firm had acquired the American pharmaceutical company’s biosimilars business in November 2022.
“Over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a unique, fully-integrated ‘lab to market’ biosimilars company," the company said in a statement.
By July this year, the company had already integrated the acquired business in 70 emerging markets, with the North American business getting integrated in September and the European business in November. “Biocon Biologics will now have a strong commercial footprint across 120 countries with a direct presence in the United States, Canada, Europe and 9 key Emerging Market countries, namely India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines," the company said.
All Viatris’ biosimilar brands will now be marketed by the Biocon Biologics teams, to ensure business continuity for various stakeholders. “...we have completed the integration of the acquired business across 120 countries.
Read more on livemint.com
